Clinical efficacy and safety were analyzed in patients with unresectable gastric cancer receiving S-1 plus CDDP(CS) therapy or S-1 plus weekly CDDP (w-CS) therapy as first-line treatment between April 2007 and December 2010. Fifteen patients received CS therapy and 17 received w-CS therapy. CS therapy was used according to the SPIRITS regimen, and w-CS therapy of S-1 80 mg/(m2·day) was administered for 2 weeks followed by a 1-week rest, with CDDP 20 mg/m2 being injected intravenously on days 1 and 8. In the CS therapy group and w-CS therapy group, the overall response rates were 33.3% and 70.1%, the median overall survival periods were 135 and 174 days (p=0.113), and the median follow- up times were 196 and 352 days (p=0.196), respectively. The w-CS therapy group showed less adverse events than did the CS therapy group. This study suggested that the w-CS regimen is a useful treatment modality showing clinical efficacy and safety for unresectable gastric cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
BMC Cancer
July 2024
Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil. Universidad de Las Palmas de Gran Canaria, Gran Canaria, Spain.
Article Synopsis
- The trial assessed the effectiveness of adding epacadostat, an IDO1 inhibitor, to pembrolizumab and chemotherapy for treating advanced non-small cell lung cancer (NSCLC) without targetable mutations.
- Patients were divided into three treatment groups: one receiving the combination of epacadostat, pembrolizumab, and chemotherapy; another receiving epacadostat and pembrolizumab; and a placebo group also receiving pembrolizumab and chemotherapy.
- Results showed that the combination of epacadostat, pembrolizumab, and chemotherapy had a lower objective response rate (26.4%) compared to the placebo combination (44.8%), indicating that adding epacadostat might not improve treatment outcomes for patients.
Background: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in non-small-cell lung cancer (NSCLC) and is the target of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. U31402-A-U102 is an ongoing phase I study of HER3-DXd in patients with advanced NSCLC. Patients with epidermal growth factor receptor (EGFR)-mutated NSCLC that progressed after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (PBC) who received HER3-DXd 5.
View Article and Find Full Text PDFPreparation and characterization of glyceryl stearate/cassava starch composite for wax therapy.
Int J Biol Macromol
March 2024
Punyapanit Company Limited, Chiang Mai 50200, Thailand. Electronic address:
Glyceryl stearate and cassava starch (CS) composites were prepared by an esterification process. Formulations containing starch at various concentrations were prepared, being 1, 1.5, 3, 5, 10, 15, 20, and 30 % by weight, respectively.
View Article and Find Full Text PDFFirst-in-human pilot trial of combined intracoronary and intravenous mesenchymal stem cell therapy in acute myocardial infarction.
Front Cardiovasc Med
August 2022
School of Medicine, China Medical University, Taichung, Taiwan.
Article Synopsis
- This study investigates the safety and effectiveness of using umbilical cord-derived stem cells to help repair heart function in patients who experienced acute STEMI and had reduced left ventricular ejection fraction (LVEF) after revascularization.
- Eight patients participated, with six completing the study, and there were no serious adverse events reported during the treatment or follow-up.
- Results showed significant improvements in heart function, including increased LVEF and decreased NT-proBNP levels, suggesting the therapy could be promising, but further research is needed.
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
J Immunother Cancer
January 2022
Experimental Cancer Medicine, The Institute of Cancer Research, London, UK
Background: Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion and thus enhancing anti-PD-1/PD-L1 efficacy.
Methods: This phase I/II study enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung cancer (NSCLC). The primary objectives of phase I were to investigate the safety and tolerability of isatuximab (anti-CD38 monoclonal antibody)+cemiplimab (anti-PD-1 monoclonal antibody, Isa+Cemi) in patients with mCRPC (naïve to anti-PD-1/PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PD-L1-containing therapy).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!